vs
Guardant Health, Inc.（GH）与Progyny, Inc.（PGNY）财务数据对比。点击上方公司名可切换其他公司
Progyny, Inc.的季度营收约是Guardant Health, Inc.的1.1倍（$318.4M vs $281.3M），Progyny, Inc.净利率更高（3.9% vs -45.7%，领先49.6%），Guardant Health, Inc.同比增速更快（39.4% vs 6.7%），Progyny, Inc.自由现金流更多（$48.6M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 7.0%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
Progyny, Inc.是总部位于美国的领先生育与家庭构建福利服务商，主要与企业雇主合作，提供试管婴儿、生育力保存、收养协助、代孕支持等综合生育相关福利方案，覆盖多个行业的雇员群体。
GH vs PGNY — 直观对比
营收规模更大
PGNY
是对方的1.1倍
$281.3M
营收增速更快
GH
高出32.7%
6.7%
净利率更高
PGNY
高出49.6%
-45.7%
自由现金流更多
PGNY
多$102.8M
$-54.2M
两年增速更快
GH
近两年复合增速
7.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $318.4M |
| 净利润 | $-128.5M | $12.5M |
| 毛利率 | 64.6% | 24.1% |
| 营业利润率 | -43.0% | 4.8% |
| 净利率 | -45.7% | 3.9% |
| 营收同比 | 39.4% | 6.7% |
| 净利润同比 | -15.8% | 18.5% |
| 每股收益（稀释后） | $-1.01 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHPGNY
| Q4 25 | $281.3M | $318.4M | ||
| Q3 25 | $265.2M | $313.3M | ||
| Q2 25 | $232.1M | $332.9M | ||
| Q1 25 | $203.5M | $324.0M | ||
| Q4 24 | $201.8M | $298.4M | ||
| Q3 24 | $191.5M | $286.6M | ||
| Q2 24 | $177.2M | $304.1M | ||
| Q1 24 | $168.5M | $278.1M |
净利润GHPGNY
| Q4 25 | $-128.5M | $12.5M | ||
| Q3 25 | $-92.7M | $13.9M | ||
| Q2 25 | $-99.9M | $17.1M | ||
| Q1 25 | $-95.2M | $15.1M | ||
| Q4 24 | $-111.0M | $10.5M | ||
| Q3 24 | $-107.8M | $10.4M | ||
| Q2 24 | $-102.6M | $16.5M | ||
| Q1 24 | $-115.0M | $16.9M |
毛利率GHPGNY
| Q4 25 | 64.6% | 24.1% | ||
| Q3 25 | 64.7% | 23.2% | ||
| Q2 25 | 65.0% | 23.7% | ||
| Q1 25 | 63.3% | 23.4% | ||
| Q4 24 | 61.6% | 21.3% | ||
| Q3 24 | 61.1% | 20.7% | ||
| Q2 24 | 59.1% | 22.5% | ||
| Q1 24 | 61.2% | 22.4% |
营业利润率GHPGNY
| Q4 25 | -43.0% | 4.8% | ||
| Q3 25 | -37.3% | 6.9% | ||
| Q2 25 | -45.9% | 7.3% | ||
| Q1 25 | -54.6% | 7.5% | ||
| Q4 24 | -62.4% | 5.3% | ||
| Q3 24 | -61.3% | 4.3% | ||
| Q2 24 | -56.8% | 6.8% | ||
| Q1 24 | -59.2% | 6.7% |
净利率GHPGNY
| Q4 25 | -45.7% | 3.9% | ||
| Q3 25 | -35.0% | 4.4% | ||
| Q2 25 | -43.0% | 5.1% | ||
| Q1 25 | -46.8% | 4.6% | ||
| Q4 24 | -55.0% | 3.5% | ||
| Q3 24 | -56.3% | 3.6% | ||
| Q2 24 | -57.9% | 5.4% | ||
| Q1 24 | -68.2% | 6.1% |
每股收益（稀释后）GHPGNY
| Q4 25 | $-1.01 | $0.14 | ||
| Q3 25 | $-0.74 | $0.15 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $0.17 | ||
| Q4 24 | $-0.90 | $0.12 | ||
| Q3 24 | $-0.88 | $0.11 | ||
| Q2 24 | $-0.84 | $0.17 | ||
| Q1 24 | $-0.94 | $0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $112.2M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $516.0M |
| 总资产 | $2.0B | $742.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHPGNY
| Q4 25 | $378.2M | $112.2M | ||
| Q3 25 | $580.0M | $134.0M | ||
| Q2 25 | $629.1M | $132.5M | ||
| Q1 25 | $698.6M | $109.2M | ||
| Q4 24 | $525.5M | $162.3M | ||
| Q3 24 | $585.0M | $91.5M | ||
| Q2 24 | $933.7M | $95.0M | ||
| Q1 24 | $1.0B | $115.0M |
总债务GHPGNY
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHPGNY
| Q4 25 | $-99.3M | $516.0M | ||
| Q3 25 | $-354.5M | $560.0M | ||
| Q2 25 | $-305.5M | $515.0M | ||
| Q1 25 | $-250.8M | $467.2M | ||
| Q4 24 | $-139.6M | $422.1M | ||
| Q3 24 | $-60.1M | $434.9M | ||
| Q2 24 | $-1.6M | $456.2M | ||
| Q1 24 | $68.3M | $571.6M |
总资产GHPGNY
| Q4 25 | $2.0B | $742.4M | ||
| Q3 25 | $1.3B | $795.2M | ||
| Q2 25 | $1.3B | $761.0M | ||
| Q1 25 | $1.3B | $730.3M | ||
| Q4 24 | $1.5B | $607.1M | ||
| Q3 24 | $1.5B | $660.0M | ||
| Q2 24 | $1.6B | $698.6M | ||
| Q1 24 | $1.7B | $794.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $54.2M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | $48.6M |
| 自由现金流率自由现金流/营收 | -19.3% | 15.3% |
| 资本支出强度资本支出/营收 | 9.9% | 1.8% |
| 现金转化率经营现金流/净利润 | — | 4.34× |
| 过去12个月自由现金流最近4个季度 | $-233.1M | $191.8M |
8季度趋势，按日历期对齐
经营现金流GHPGNY
| Q4 25 | $-26.4M | $54.2M | ||
| Q3 25 | $-35.4M | $50.7M | ||
| Q2 25 | $-60.3M | $55.5M | ||
| Q1 25 | $-62.7M | $49.8M | ||
| Q4 24 | $-64.5M | $52.2M | ||
| Q3 24 | $-51.1M | $44.5M | ||
| Q2 24 | $-94.0M | $56.7M | ||
| Q1 24 | $-30.3M | $25.7M |
自由现金流GHPGNY
| Q4 25 | $-54.2M | $48.6M | ||
| Q3 25 | $-45.8M | $46.0M | ||
| Q2 25 | $-65.9M | $50.2M | ||
| Q1 25 | $-67.1M | $47.0M | ||
| Q4 24 | $-83.4M | $50.3M | ||
| Q3 24 | $-55.3M | $42.7M | ||
| Q2 24 | $-99.1M | $55.8M | ||
| Q1 24 | $-37.2M | $24.9M |
自由现金流率GHPGNY
| Q4 25 | -19.3% | 15.3% | ||
| Q3 25 | -17.3% | 14.7% | ||
| Q2 25 | -28.4% | 15.1% | ||
| Q1 25 | -33.0% | 14.5% | ||
| Q4 24 | -41.3% | 16.8% | ||
| Q3 24 | -28.9% | 14.9% | ||
| Q2 24 | -55.9% | 18.4% | ||
| Q1 24 | -22.1% | 8.9% |
资本支出强度GHPGNY
| Q4 25 | 9.9% | 1.8% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 2.4% | 1.6% | ||
| Q1 25 | 2.2% | 0.9% | ||
| Q4 24 | 9.4% | 0.6% | ||
| Q3 24 | 2.2% | 0.6% | ||
| Q2 24 | 2.9% | 0.3% | ||
| Q1 24 | 4.1% | 0.3% |
现金转化率GHPGNY
| Q4 25 | — | 4.34× | ||
| Q3 25 | — | 3.65× | ||
| Q2 25 | — | 3.24× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | — | 4.95× | ||
| Q3 24 | — | 4.27× | ||
| Q2 24 | — | 3.44× | ||
| Q1 24 | — | 1.52× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PGNY
| Fertility Benefit Services | $208.6M | 66% |
| Pharmacy Benefit Services | $109.8M | 34% |
